AbbVie (ABBV) Advances While Market Declines: Some Information for Investors

AbbVie stock rose 1.78% to $261.70, outperforming a declining S&P 500. The company has gained 3.07% over the past month, exceeding sector losses. Analysts expect strong earnings growth of 107.53% YoY with revenue projected at $17.36 billion (+10.02% YoY). AbbVie holds a Zacks Rank #3 (Hold) with a Forward P/E of 18.3, trading at a premium to its industry average.